A green light has been lit for the reimbursement of BMS Korea’s leukemia treatment ‘Onureg tab,’ with its agenda passing deliberations for setting reimbursement standards.

Also, reimbursement standards have been prepared for 5 neutropenia treatment products including Hanmi Pharmaceutical’s Rolontis.

The Health Insurance Review and Assessment Service’s Cancer Disease Deliberation Committee (CDDC) held its 10th meeting on the 14th and made the deliberations above.

First, Onureg tab (azacitidine, BMS Korea), which is attempting to establish a new reimbursement category,
succeeded in establishing reimbursement standards as ‘maintenance therapy in adult patients wit